Dexmedetomidine and Outcomes of Elderly Admitted to ICU After Surgery

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,410

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2026

Conditions
ElderlySurgeryIntensive Care UnitDexmedetomidineOverall Survival
Interventions
DRUG

Dexmedetomidine

"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."

DRUG

Placebo

"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

collaborator

Beijing Hospital

OTHER_GOV

lead

Peking University First Hospital

OTHER